Sun Pharmaceutical Industries Limited (better known as Sun Pharma) is eyeing major expansion plans after the Indian biopharma company announced plans to acquire Organon late last month.
Let’s take this from the top—starting with Sun Pharma.
Headquartered in Mumbai, India, Sun Pharma is known as one of the largest specialty generic pharmaceutical companies across the globe.
What it does: Manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in 100+ countries, including the United States.
Its portfolio consists of retail and specialty innovative medicines, generics, and consumer healthcare products targeting a wide spectrum of chronic and acute diseases.
And in the ophthalmic space?
Two well-known therapies include:
- CEQUA (cyclosporine ophthalmic solution) 0.09%
- BromSite (bromfenac ophthalmic solution) 0.075%
- Indicated for the treatment of postoperative inflammation and prevention of ocular pain for patients undergoing cataract surgery
- See here for details on this nonsteroidal anti-inflammatory drug (NSAID).
And in the generic space: ketorolac tromethamine ophthalmic solution (0.50% and 0.0005%) and loteprednol ophthalmic suspension (0.5%/5 mL; 0.5%/10 mL; 0.5%/15 mL)
Now talk about Organon.
The Jersey City, New Jersey-headquartered global healthcare company was formed in 2021 as a spinoff from Merck.
Its portfolio consists of 70+ products (biosimilars included) commercialized across 140 countries within the women’s health and general medications spaces.
- See here for its complete product list.
Next up: this proposed deal.
Per the definitive agreement, Sun Pharma will acquire all outstanding shares of Organon (at $14 per share) as part of an all-cash (yes, you read that right) transaction.
In total (in case you missed our headline), the deal’s value is expected to clock in at $11.75 billion.
So how is Sun Pharma funding this?
The company shared plans to use a combination of available cash resources and “committed financing" from banks.
- As for the Oragonon merger itself: This will be through an (unnamed) subsidiary of Sun Pharma.
Pending the transaction’s closing, Sun Pharma is expected to have a combined revenue of $12.4 billion. Check out the other advantages the company stands to gain.
… and when might the deal close?
The anticipated timeframe: Early 2027.
To note: This is subject to customary conditions, such as regulatory approvals and approval from Organon’s stockholders; both companies' boards have already granted approval.
Big plans—and quite the price tag. But how does this deal relate to eyecare?
On the surface, it doesn’t. However, if we dig a little deeper … this is a strategic move on Sun Pharma’s part, particularly in the potential for future ophthalmic product development.
Case in point: The deal expands the company’s overall specialty commercial infrastructure by:
- Strengthening its established branded / branded generics portfolio
- Positioning it as a global leader in the biosimilar space
- Sun Pharma will be ranked #7 among the top global biosimilar sellers—a much needed boost for the company, as reports have noted its U.S. sales have declined recently.
And has the company commented on this deal yet?
As Sun Pharma’s Kirti Ganorkar, managing director, stated: “This transaction is a logical next step in strengthening (out) global business.”
- See here for more comments from both companies.
However, only time will tell what the company’s expansion plans may actually look like—including within the ophthalmic branded, generic, and biosimilar space.
As always, stay tuned for updates on this front!